TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $144.25.

TMDX has been the topic of a number of recent analyst reports. Canaccord Genuity Group raised their target price on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, February 14th. Morgan Stanley lifted their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Needham & Company LLC boosted their price objective on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a report on Monday, December 8th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd.

TransMedics Group Stock Performance

TMDX stock opened at $134.25 on Friday. TransMedics Group has a twelve month low of $62.07 and a twelve month high of $156.00. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. The company has a market cap of $4.59 billion, a P/E ratio of 54.35 and a beta of 2.06. The business’s fifty day moving average is $132.50 and its 200-day moving average is $125.87.

Insider Activity at TransMedics Group

In related news, Director David Weill sold 5,000 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the sale, the director owned 12,134 shares of the company’s stock, valued at approximately $1,682,257.76. This trade represents a 29.18% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the transaction, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 8,920 shares of company stock worth $1,257,310 in the last quarter. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently modified their holdings of TMDX. Vanguard Group Inc. raised its holdings in TransMedics Group by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company’s stock worth $404,549,000 after buying an additional 9,650 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of TransMedics Group by 11.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after acquiring an additional 113,817 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of TransMedics Group by 50.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock worth $117,506,000 after acquiring an additional 322,353 shares during the period. Geode Capital Management LLC raised its holdings in shares of TransMedics Group by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock worth $99,339,000 after acquiring an additional 2,903 shares during the period. Finally, Two Sigma Investments LP lifted its position in TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after acquiring an additional 223,409 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.